Tuesday 21 February 2017

Relapsed Multiple Myeloma - Pipeline Review, H1 2015: Create Effective Counter Strategies to gain Competitive Advantage

ResearchMoz added Latest Research Report titled " Relapsed Multiple Myeloma - Pipeline Review, H1 2015 " to it's Large Report database.

Global Markets Direct’s, ‘Relapsed Multiple Myeloma Pipeline Review, H1 2015’, provides an overview of the Relapsed Multiple Myeloma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=279929

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8

Introduction 9
Global Markets Direct Report Coverage 9
Relapsed Multiple Myeloma Overview 10
Therapeutics Development 11
Pipeline Products for Relapsed Multiple Myeloma - Overview 11
Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis 12
Relapsed Multiple Myeloma - Therapeutics under Development by Companies 13
Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 17
Relapsed Multiple Myeloma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Relapsed Multiple Myeloma - Products under Development by Companies 20
Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes 25
Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development 26
4SC AG 26
AB Science 27
AbbVie Inc. 28
Acceleron Pharma, Inc. 29
Acetylon Pharmaceuticals, Inc. 30
Altor BioScience Corporation 31
Arno Therapeutics, Inc. 32
Array BioPharma Inc. 33
Astellas Pharma Inc. 34
Astex Pharmaceuticals, Inc. 35

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment